Edition:
United States

Merck KGaA (MKGAY.PK)

MKGAY.PK on OTC Markets Group

37.39USD
3:23pm EDT
Change (% chg)

$-0.35 (-0.92%)
Prev Close
$37.74
Open
$37.63
Day's High
$37.63
Day's Low
$37.30
Volume
60,934
Avg. Vol
5,650
52-wk High
$38.00
52-wk Low
$27.44

Select another date:

Thu, Mar 23 2017

FDA approves Pfizer, German Merck immunotherapy for skin cancer

U.S. health regulators on Thursday approved a drug developed by Merck KGaA and Pfizer Inc that helps the immune system to fight a rare form of skin cancer once it has spread to other parts of the body.

FDA approves Pfizer, German Merck immunotherapy for skin cancer

March 23 U.S. health regulators on Thursday approved a drug developed by Merck KGaA and Pfizer Inc that helps the immune system to fight a rare form of skin cancer once it has spread to other parts of the body.

BRIEF-Merck KGaA announces release of two fertility technologies products

* release of 2 fertility technologies products for improved efficiency in assisted reproductive treatment lab, eevatest 3.0, geri humidified incubation Source text for Eikon: Further company coverage:

Development costs to keep Merck KGaA profit flat this year

FRANKFURT German drugs and lab supplies maker Merck KGaA forecast stagnant earnings for 2017 as it spends more on developing a cancer drug it hopes will revive the fortunes of its pharmaceuticals division.

UPDATE 2-Development costs to keep Merck KGaA profit flat this year

* Drug seen as dictating future of pharma business (Adds study adjustment, shares)

Germany's Merck well advanced in talks to sell biosimilars unit

DARMSTADT, Germany Germany's Merck KGaA on Thursday said it was seeking a buyer for its biosimilars unit, confirming a Reuters report in October.

Germany's Merck well advanced in talks to sell biosimilars unit

DARMSTADT, Germany, March 9 Germany's Merck KGaA on Thursday said it was seeking a buyer for its biosimilars unit, confirming a Reuters report in October.

Merck KGaA predicts stable adj EBITDA in 2017

FRANKFURT, March 9 German drugs and lab supplies maker Merck KGaA forecast stagnant core earnings for 2017 as strong demand for its biotech lab and production supplies is likely to be offset by competition for its main prescription drugs.

BRIEF-Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on BGB-283

* Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on continuation option to develop, commercialize BGB-283 outside China Source text for Eikon: Further company coverage:

BRIEF-Merck says NICE expands a positive recommendation for Erbitux

* Says NICE expands positive recommendation for Erbitux as first-line treatment for RAS Wild-type mCRC Source text: http://news.merck.de/EMD/CC/NewsRelease.nsf/0/F18F0B124700BF92C12580D5003C2A1C/$FILE/Erbitux_NICE_Eng.pdf Further company coverage:

Select another date:

More From Around the Web